Table 2. Assessment of the selective BEAV broth plus MALDI-TOF MS (SBEAVM) method for the detection of VRE in selected patients.
| Incubation period (hours) | Purpose | Number of | Sensitivity (%) |
Specificity (%) |
PPV (%) |
NPV (%) |
|||
|---|---|---|---|---|---|---|---|---|---|
| TP | FP | TN | FN | ||||||
| 20 | ASC | 11 | 0 | 52 | 9 | 55.0 | 100.0 | 100.0 | 85.3 |
| FUC | 20 | 1 | 19 | 23 | 46.5 | 95.0 | 95.2 | 45.2 | |
| 24 | ASC | 16 | 2 | 50 | 4 | 80 | 96.2 | 88.9 | 92.6 |
| FUC | 40 | 4 | 16 | 3 | 93.0 | 80.0 | 90.9 | 84.2 | |
| 28 | ASC | 18 | 3 | 49 | 2 | 90.0 | 94.2 | 85.7 | 96.1 |
| FUC | 41 | 4 | 16 | 2 | 95.3 | 80.0 | 91.1 | 88.9 | |
The screening method was used for the ASC of high-risk patients without VRE colonization or infection during the previous 6 months.
The screening method was used for the FUC of patients with VRE colonization or infection during the previous 6 months.
BEAV, bile esculin azide broth with vancomycin; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; SBEAVM, selective BEAV broth plus MALDI-TOF MS identification; VRE, vancomycin-resistant Enterococci; TP, true positive; FP, false positive; TN, true negative; FN, false negative; ASC, active surveillance culture; FUC, follow-up culture